LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Additional trials underway Ongoing trials are now focused on bigger, long-term questions, like how it performs over time across different groups of people and whether it offers additional health benefits
Habits, Health, and Psychological Resilience Understanding how habits sustain or erode well-beingconsidering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts
Blom AM, Kask L, Ramesh B, Hillarp A